TYRA - Tyra Biosciences, Inc.
IEX Last Trade
14.54
0.060 0.413%
Share volume: 6,490
Last Updated: Thu 26 Dec 2024 08:26:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$14.48
0.06
0.41%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.12%
1 Month
-10.37%
3 Months
-39.79%
6 Months
-10.82%
1 Year
-3.29%
2 Year
59.93%
Key data
Stock price
$14.54
DAY RANGE
$13.74 - $14.52
52 WEEK RANGE
$12.06 - $29.60
52 WEEK CHANGE
$1.37
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Todd J. Harris
Region: US
Website: tyra.bio
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: tyra.bio
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Tyra Biosciences, Inc. focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
Recent news